Angiotensin Converting Enzyme 2 News and Research

RSS

Melatonin could be a potential therapy for long-COVID symptoms

A recent review published in the journal Biomolecules discussed the potential uses of melatonin in treating brain fog, and chronic fatigue syndrome or myalgic encephalomyelitis symptoms associated with long coronavirus disease (COVID)

9 Nov 2022

The direct and indirect effects of COVID-19 on people with type 1 and type 2 diabetes

A recent study published in The Lancet Diabetes & Endocrinology discussed the impact of COVID-19 on individuals with diabetes.

9 Nov 2022

Study indicates widespread SARS-CoV-2 exposure in wildlife

In a recent study posed to the bioRxiv* preprint server, researchers at Virginia Tech University investigated wildlife exposure to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).

8 Nov 2022

Does vitamin D reduce COVID-19 severity?

A new study examined published studies for a consistent association between vitamin D levels and coronavirus disease 2019 (COVID-19) severity.

8 Nov 2022

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

Researchers recently measured the neutralizing antibody titers against the wild-type strain of SARS-CoV-2 and the SARS-CoV-2 Omicron subvariants in healthcare workers fully vaccinated with three doses of the Comirnaty vaccine who experienced breakthrough Omicron infections.

8 Nov 2022

COVID-19 amplifies damage to the central nervous system in Alzheimer's disease

In a recent study published in the journal Annals of Diagnostic Pathology, researchers in the United States evaluated the impact of coronavirus disease 2019 (COVID-19) on central nervous system (CNS) damage in Alzheimer's disease (AD).

7 Nov 2022

SARS-CoV-2 activates NLRP3 inflammasome

Researchers assessed the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation.

7 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

Scientists identify a cryptic SARS-CoV-2 lineage in wastewater

In a recent study posted to the medRxiv* preprint server, researchers in the United States investigated the source of an enigmatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)-like spike (S) protein strain detected in wastewater but not in clinical samples.

2 Nov 2022

Vimentin is an important co-receptor for SARS-CoV-2 infection

Vimentin functions as a co-receptor for the entry of SARS-CoV-2 into host cells to facilitate infection.

2 Nov 2022

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

2 Nov 2022

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Researchers examined how imprinted SARS-CoV-2 humoral immunity drives convergent evolution in continuously emerging Omicron subvariants.

2 Nov 2022

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

A new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novavax protein nanoparticle vaccine NVX-CoV2373.

31 Oct 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

A new study confirmed that the SARS-CoV-2 spike protein does not bind to human AChR’s orthosteric sites, nor does it compete with ACh, choline, or nicotine.

28 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Long COVID, a new clinical entity constantly evolving

Researchers discuss the epidemiology, diagnosis, pathogenesis, and treatment of long COVID.

27 Oct 2022

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

Researchers explore the thermodynamic properties of the SARS-CoV-2 Omicron subvariant BA.2.75 to understand its increased transmissibility.

27 Oct 2022

Vaccination- and/or natural infection-induced immune responses against SARS-CoV-2 Omicron subvariants

Researchers comparatively evaluated the neutralization antibody titers for SARS-CoV-2 Omicron VOC subvariants BA.1, BA.2, BA.4/5 among individuals with ancestral B.1 strain infections, vaccinated individuals, or with hybrid immunity from breakthrough infections and vaccinations with Delta or Gamma VOCs.

27 Oct 2022

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Researchers reported three human monoclonal antibodies generated from COVID-19-recovered individuals during the initial wave of the pandemic in India.

27 Oct 2022

Angiotensin Converting Enzyme 2 News and Research

Melatonin could be a potential therapy for long-COVID symptoms

The direct and indirect effects of COVID-19 on people with type 1 and type 2 diabetes

Study indicates widespread SARS-CoV-2 exposure in wildlife

Does vitamin D reduce COVID-19 severity?

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

COVID-19 amplifies damage to the central nervous system in Alzheimer's disease

SARS-CoV-2 activates NLRP3 inflammasome

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Scientists identify a cryptic SARS-CoV-2 lineage in wastewater

Vimentin is an important co-receptor for SARS-CoV-2 infection

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

Long COVID, a new clinical entity constantly evolving

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

Vaccination- and/or natural infection-induced immune responses against SARS-CoV-2 Omicron subvariants

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News